NYSE · Healthcare · Drug Manufacturers - General · USA
Lilly(Eli) & Co is a mega cap company (market value over $200 billion) in the Drug Manufacturers - General industry.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic health, oncology, immunology, and neuroscience therapeutic areas. The company operates manufacturing facilities in the United States, Europe, and Asia, selling its products worldwide through wholesalers, direct distribution channels, and partnerships with healthcare organizations and other pharmaceutical companies.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Lilly(Eli) & Co stock.
Overvalued: intrinsic value $876.12 per share, market price $1240.34, margin of safety -41.6% (as of 2026-10-19).
Discounting its cash flows at 7.9% (average of 3 methods) values the shares at $876.12; the price of $1,240.34 is 42% above that value, and 81% of that value comes from beyond year five.
Leak Score: 59/100 on 11 of 12 signals (Weak Signal).
17 more funds hold it; the full list is part of the paid plan.
All 21 Drug Manufacturers - General stocks
5 more in this industry show a wider margin of safety.
LLY is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 7.9% (average of 3 methods) values the shares at $876.12; the price of $1,240.34 is 42% above that value, and 81% of that value comes from beyond year five.
$876.12 per share (as of the 2026-10-19 close), against a market price of $1240.34. That is a margin of safety of -41.6%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
The price needs faster growth than we project for any company. It is betting on an exception. Yearly sales growth the price needs: 35.2%. Yearly sales growth it has sustained: 19.6%.
59 out of 100, which we rate "Weak Signal", on 11 of 12 value investing signals.